Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- FNCH
- Price
- -
- Stock movement up
- +- (0.00%)
- Company name
- Finch Therapeutics Group Inc
- Exchange
- (PINK ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 19.27M
- Ent value
- 34.59M
- Price/Sales
- 3.39
- Price/Book
- 1.36
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return (CAGR)
- 258.21%
- 3 year return (CAGR)
- -66.91%
- 5 year return (CAGR)
- -
- 10 year return (CAGR)
- -
Last updated: 2024-12-17
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
FNCH does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 3.39 |
| Price to Book | 1.36 |
| EV to Sales | 6.08 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 1.61M |
| EPS (TTM) | -8.82 |
| FCF per share (TTM) | -11.25 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 5.69M |
| Gross profit (TTM) | 2.71M |
| Operating income (TTM) | -19.73M |
| Net income (TTM) | -14.17M |
| EPS (TTM) | -8.82 |
| EPS (1y forward) | - |
Margins
Loading...
Margins data
| Gross margin (TTM) | 47.56% |
| Operating margin (TTM) | -346.84% |
| Profit margin (TTM) | -248.98% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 16.04M |
| Net receivables | 0.00 |
| Total current assets | 17.28M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 26.35M |
| Total assets | 45.58M |
| Accounts payable | 29.00K |
| Short/Current long term debt | 28.99M |
| Total current liabilities | 4.46M |
| Total liabilities | 31.36M |
| Shareholder's equity | 14.22M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -18.05M |
| Capital expenditures (TTM) | 28.00K |
| Free cash flow (TTM) | -18.07M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -99.63% |
| Return on Assets | -31.08% |
| Return on Invested Capital | -86.84% |
| Cash Return on Invested Capital | -110.76% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
No data
Stock price data
| Open | 12.00 |
| Daily high | 12.00 |
| Daily low | 12.00 |
| Daily Volume | 0K |
| 1y analyst estimate | 90.00 |
| Beta | 1.33 |
| EPS (TTM) | -8.82 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| FNCH | S&P500 | |
| Current price drop from All-time high | -98.12% | -0.59% |
| Highest price drop | -99.86% | -56.47% |
| Date of highest drop | 29 May 2024 | 9 Mar 2009 |
| Avg drop from high | -81.18% | -10.84% |
| Avg time to new high | 943 days | 12 days |
| Max time to new high | 942 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
19.27M
Marketcap category
Small-cap
Description
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; and license agreements with Skysong Innovations LLC, OpenBiome, Arizona State University, and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Boston, Massachusetts.
Employees
1
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page